Bioventus BVS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Net Sales by Business | ||||||
| International Segment | $15.64M+17.1% | $18.41M-0.1% | $15.34M-4.5% | $18.89M+12.4% | $13.36M-12.0% | |
| U.S. Segment | $116.45M+5.4% | $139.49M+3.2% | $123.31M+0.3% | $128.78M-4.2% | $110.52M-3.3% | |
| Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items by Business | ||||||
| International Segment | $2.77M+28.6% | $4.71M+22.8% | $3.17M-18.7% | $5.28M+84.3% | $2.16M-24.8% | |
| U.S. Segment | $21.14M+24.0% | $32M+31.1% | $23.44M+19.2% | $28.48M-9.9% | $17.06M-13.7% | |
| Adjusted other segment expense by Business | ||||||
| International Segment | -$120K-6,100% | $0+100% | $16K+103% | $170K+46.6% | $2K-99.3% | |
| U.S. Segment | -$252K-128% | $81K+298% | $200K+255% | $366K+713% | $899K+496% | |
| Adjusted cost of sales by Business | ||||||
| International Segment | $6.34M+22.8% | $7.06M+7.8% | $5.89M+7.0% | $6.75M+0.8% | $5.16M-5.2% | |
| U.S. Segment | $24.9M-2.0% | $31.67M-6.3% | $28.54M-3.9% | $28.22M-5.5% | $25.4M-0.8% | |
| Adjusted research and development expense by Business | ||||||
| International Segment | $0-100% | $16K+60.0% | $4K-69.2% | $18K+125% | $3K-70.0% | |
| U.S. Segment | $2.29M-19.0% | $2.83M-9.9% | $2.7M-24.2% | $2.92M-17.1% | $2.83M-3.4% | |
| Adjusted general and administrative expense by Business | ||||||
| International Segment | $2.58M+31.3% | $2.46M-47.8% | $2.39M-34.4% | $2.52M-28.8% | $1.97M-36.0% | |
| U.S. Segment | $24.24M+4.0% | $24.99M+2.8% | $24.4M-3.6% | $24.79M+0.7% | $23.32M-0.1% | |
| Adjusted selling expense by Business | ||||||
| International Segment | $3.32M+3.8% | $3.33M+16.2% | $2.94M+4.3% | $3.22M+19.5% | $3.2M+12.1% | |
| U.S. Segment | $38.24M+10.2% | $42.09M-3.0% | $37.92M-1.9% | $37.35M-3.6% | $34.72M-6.1% | |
| Adjusted marketing expense by Business | ||||||
| International Segment | $753K-13.5% | $854K+9.1% | $930K+35.4% | $933K+4.6% | $871K+35.7% | |
| U.S. Segment | $5.89M-6.7% | $5.83M-5.7% | $6.12M0.0% | $6.66M+10.1% | $6.31M+7.3% | |
| Total Net Sales by Product | ||||||
| Pain Treatments | $63.43M+7.7% | $79.66M+15.1% | $67.18M+6.4% | $73.31M+1.5% | $58.92M+3.9% | |
| Restorative Therapies | $20.64M+4.6% | $22.71M-26.0% | $21.31M-28.8% | $21.64M-31.6% | $19.72M-35.3% | |
| Surgical Solutions | $48.03M+6.2% | $55.53M+3.4% | $50.17M+9.3% | $52.72M+11.4% | $45.23M+7.0% | |
| Total Net Sales by Geography | ||||||
| International | $15.64M+17.1% | $18.41M-0.1% | $15.34M-4.5% | $18.89M+12.4% | $13.36M-12.0% | |
| U.S. | $116.45M+5.4% | $139.49M+3.2% | $123.31M+0.3% | $128.78M-4.2% | $110.52M-3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
